No added value for a drug's new indication? Price should adjust, researchers say
06 Jul 2023
Accelerated ApprovalDrug Approval
As more follow-on treatments with incremental improvements win approval in the US and Europe, new research published yesterday notes that fewer than half of the first indication approvals for new drugs in the US and Europe were rated as having high therapeutic value.
Therapeutic value was determined in the study by ratings for first and supplemental indications made by France’s Ministry of Health and Germany’s Federal Joint Committee, based on evaluations and re-evaluations of drugs conducted and published as of December 2022.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.